There is a particular kind of medical blind spot that the NHS has never been equipped to address. It’s not the dramatic kind, not a missed tumour or a misread scan. It’s quieter and, in many ways, more insidious. And it’s the gap between feeling broadly fine and actually being fine.
And new data from inside the preventive health movement suggests that the gap is far wider than most British people would care to admit.
Over the past decade, a generation of health-conscious consumers has graduated from step-counting and calorie-tracking to something more rigorous: biomarker testing. The idea is straightforward.
Rather than waiting for symptoms to surface, you measure what’s actually happening inside your body: your cholesterol fractions, your thyroid function, your inflammatory markers, your hormone balance, and you act on what the numbers tell you before a GP has any clinical reason to call.
It’s a model that has taken root in the United States and Scandinavia far more aggressively than it has here.
But that is changing, and the data emerging from UK-based platforms is starting to paint a striking picture of what British people don’t know about their own health.
The Numbers That Should Make You Stop
Emerald, the London-based preventive health platform that combines biomarker testing with dedicated private GP support and AI-driven health planning, recently published an analysis drawn from 25,000 biomarker tests conducted on its UK members. The headline finding is arresting: Emerald data: 53% have raised cholesterol.
Sit with that figure for a moment. More than half of the people who proactively sought out comprehensive health screening, people motivated enough to pay for it, book it, and turn up, were carrying cholesterol levels that should prompt clinical attention.
These are not patients who came in complaining of chest tightness or shortness of breath.
These are people who, by any reasonable measure, thought they were well. They exercised.
And yet more than one in two were walking around with a cardiovascular risk factor ticking away unremarked.
This is not a story about hypochondria or the medicalisation of normal life. This is a story about what happens when you finally look.
Why Britain Is So Far Behind
The structural problem is well understood, even if it remains largely unaddressed. The NHS operates, by necessity and design, as a reactive system. GPs are trained and incentivised to respond to presenting symptoms, not to go hunting for silent risk.
A standard NHS health check available to those between 40 and 74 once every five years covers a handful of markers: blood pressure, BMI, cholesterol, and blood glucose. It is, in clinical terms, a blunt instrument.
What comprehensive biomarker testing adds is granularity. The difference between knowing your “total cholesterol” and understanding your LDL particle number, your ApoB levels, your HDL-to-triglyceride ratio, and how those figures interact with your inflammatory markers and family history is the difference between a rough map and a GPS.
One tells you there’s a mountain somewhere ahead. The other tells you exactly where you’re standing.
That granularity has historically come at a price that made it inaccessible to most people. To screen comprehensively for common disease markers and those specific to your individual profile in the UK today costs upwards of £1,000, and that’s before the cost of a clinician who can actually interpret the results in context and advise you on what to do next.
For the majority of the population, that threshold is simply prohibitive.
The Demand Signal Is Impossible to Ignore
What’s changed is that platforms are now making comprehensive screening economically viable at scale, and in doing so, they are generating a body of real-world data that the traditional healthcare system cannot match. Emerald’s 25,000-test dataset isn’t a clinical trial.
It isn’t a self-selected survey with a convenient sample. It’s a window into what people actually look like on the inside when someone finally takes the time to look properly.
And the cholesterol finding is unlikely to be the most troubling one. It’s the most legible, because raised cholesterol has a clear cultural frame around it.
But chronic vitamin D deficiency, subclinical thyroid dysfunction, insulin resistance that hasn’t yet tipped into a formal diagnosis, hormonal imbalances that quietly erode energy and mood and sleep, these are the categories where the gap between the felt experience of health and the biochemical reality tends to be widest.
The symptoms are vague. The conditions are progressing. And without a test, there is simply no mechanism to know.
The Case for Personalisation
What makes Emerald’s model and the broader shift it represents, more than a premium wellness product, is the recognition that screening without action is nearly worthless.
This is the part of the preventive health equation that even well-funded platforms sometimes get wrong.
A long printout of biomarker results, however comprehensive, doesn’t change behaviour. What changes behaviour is a coherent interpretation, a clear set of priorities, and a relationship with someone qualified to translate numbers into actions.
Emerald’s architecture is built around this problem. For £299 a year, members receive two lab visits covering over 115 biomarkers, a dedicated private GP who provides one-to-one coaching, and an AI-driven health action plan, reviewed and approved by its own medical team before being shared with members.
The system integrates fitness wearables, allows members to upload and track past health reports, and generates referral letters if abnormalities require specialist attention.
The result is something the NHS cannot currently offer: a living health roadmap, updated as your data updates, responsive to your specific biology rather than population-level averages.
That last point is worth dwelling on. The application of population-level thinking to individual health is the original sin of how we currently discuss and manage chronic disease risk. You are not the average 42-year-old.
Your risk profile for cardiovascular disease, type 2 diabetes, or a thyroid disorder is shaped by your specific biomarkers, your family history, your activity levels, your sleep quality, and a dozen other variables that a once-every-five-years NHS health check was never designed to capture.
Emerald’s AI is trained on thousands of peer-reviewed clinical papers and checked by clinicians before any recommendation reaches a member is attempting to solve this problem precisely at scale.
What “Preventive” Actually Means Now
The language of prevention has been degraded by wellness culture to the point where it has become nearly meaningless.
Detox teas prevent nothing. Cold plunges prevent nothing. Supplements taken without any understanding of whether you’re actually deficient in anything they contain prevent nothing.
Real prevention is upstream medicine: catching the signals that precede disease and redirecting the trajectory before the clinical threshold is crossed.
The 53% raised cholesterol figure from Emerald’s data is a case study in what real prevention looks like in practice. Half of those people, unscreened, would likely have had no reason to suspect anything was wrong.
They would have continued eating the same foods, carrying the same risk, until perhaps years or decades later, a GP had a clinical reason to check. Some of them would have been fine. Some of them would not.
The scale of undetected risk in a country where comprehensive screening costs more than most people earn in a week is not primarily a story about individual responsibility. It is a structural problem with structural solutions.
But in the absence of those systemic changes arriving quickly, the growth of accessible, data-rich preventive health platforms represents something that is genuinely new: a mechanism for ordinary people to close the gap between how they feel and what is actually happening inside them before it becomes something that cannot be undone.
The Long Game
Emerald’s long-term goal is unambiguous. The company wants to give every person in Britain who wants one their own personalised preventive health action plan, housed in a single app, evolving as their data evolves.
That ambition reflects a conviction that the demand for this kind of rigorous, longitudinal, personalised health intelligence is not a niche wellness trend. It is a rational response to a healthcare system that was never designed to meet it.
The 25,000 tests are a beginning. The real story will be what happens when people act on what they find and what the data looks like a generation from now if they do.
Emerald offers annual memberships from £299, covering 115+ biomarkers, dedicated GP support, AI-driven health planning, and wearables integration. Find out more at withemerald.com
